With the support of Bluegreen, PlumeStars SRL secured over €130,000 in funding from Invitalia through the national Brevetti+ program.
PlumeStars is an innovative SME, originally founded as a startup in 2013 by pharmaceutical technology researchers from the University of Parma, to develop a patent for inhalable antibiotic powders. The founders focus on the research and development of medicines based on advanced pharmaceutical technologies, particularly for inhalation drug delivery. Their research activity is dedicated to the formulation of advanced medicines, including treatments for rare diseases.
PlumeStars’ innovative research focuses on:
- The development of nano- and microparticles containing drugs and their use in formulations for local or systemic administration;
- Inhalable antibiotic powders for the treatment of lung infections;
- Biodegradable films containing anticancer agents for the local treatment and prevention of recurrence of sensitive tumors;
- Nasal powders with antiviral agents for upper respiratory tract infections, such as SARS-CoV-2.
About the project
Covinhale is a nasal powder that blocks viral replication in the early stages of infection in the upper airways. The active ingredient is chloroquine, a drug shown to be effective against SARS-CoV-2 across all known variants.